ExThera Medical Announces FDA Approval of IDE Application for Use of the OncoBind Extracorporeal Procedure to Remove Circulating Tumor Cells in Patients With Pancreatic Cancer

Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

Survival Benefit With Checkpoint Inhibitors Versus Chemotherapy is Modified by Brain Metastases in Patients With Recurrent Small-Cell Lung Cancer

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

ChatGPT's Limited Ability to Recommend Guideline-Based Cancer Treatments

Response Assessment of Post-Treatment Head and Neck Cancers to Determine Further Management Using NI-RADS (Neck Imaging Reporting and Data System): A Subgroup Analysis of a Randomized Controlled Trial

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

ExThera Medical Announces FDA Approval of IDE Application for Use of the OncoBind Extracorporeal Procedure to Remove Circulating Tumor Cells in Patients With Pancreatic Cancer

header-info

Jul, 14, 2023

Researchers will begin recruiting patients into a clinical study to determine the efficacy of oncobind, an extracorporeal blood filter procedure, and if it can be used to remove circulating tumor cells from the blood of patients with pancreatic ductal adenocarcinoma.

Access the full article to read more here.